$MannKind(MNKD)$ MannKind has a promising pipeline that's moving forward.
Here's a breakdown of potential share price contributions from various approvals and events, based on my view, before the end of 2028:
+ $4 – acquisition of scPharma ($Scpharmaceuticals Inc.(SCPH)$ )
+ $4 – label change for Afrezza
+ $2 – Afrezza in India
+ $6 – pediatric Afrezza
+ $8 – FDA approval of the Furoscix auto injector
+ $2 – gestational Afrezza
+ $6 – Ralinepag DPI (MNKD-1501, $United Therapeutics(UTHR)$ )
+ $7 – Nintedanib DPI (MNKD-201)
+ $3 – Bumetanide DPI (MNKD-701)
+ $6 – Tyvaso DPI bridge for IPF & PPF
+ $? – Undisclosed drug
That adds up to a potential $48 per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
